Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 30th May 2019
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Researchers set to develop African Swine Fever antivirals
"Having a tool which could lower the risk of further transmission once pigs have been infected would go a long way in preventing the rapid spread of this disease" - Dr Linda Dixon.
Study will help scientists understand how the virus infects pigs

The first antiviral drugs that are effective against African Swine Fever (ASF) are set to be developed by researchers at The Pirbright Institute.

It is hoped that in the absence of a vaccine, antiviral drugs could offer an alternative method of control that would help limit clinical signs in pigs and reduce virus replication. In turn, this would minimise disease spread and help to contain outbreaks, ultimately reducing the number of pigs lost to this fatal infection.

Working with Belgian biotechnology firm ViroVet, the researchers will test antiviral drugs that have already been screened in the laboratory and shown to reduce viral replication in the absence of cellular toxicity. Up to now, the antivirals have shown a minimum of 90 per cent reduction in viral replication. The candidates that are most successful will undergo further testing at Pirbright’s high containment facilities.

Dr Linda Dixon, head of the African Swine Fever group at Pirbright, said: “The unique experience of ViroVet makes them the ideal company to partner with on this project. The results from this study will help us understand more about how the virus infects pigs and will help to inform our vaccine development research.

“Without a viable vaccine, ASF is incredibly difficult to control owing to its ability to be spread by wild boar and through the consumption of contaminated pork and other products by pigs. Having a tool which could lower the risk of further transmission once pigs have been infected would go a long way in preventing the rapid spread of this disease.”
 
Dr Nesya Goris, chief development officer and co-founder of ViroVet added: “This joint research will help us select a potent antiviral drug that could stop transmission of ASF from infected animals and prevent spread to healthy pigs.

“We are extremely proud and honoured to partner with the expert scientists of The Pirbright Institute. The study will help advance the new concept of ASF containment using antiviral drugs.”

Become a member or log in to add this story to your CPD history

Rabbit Awareness Week set to return this summer

News Story 1
 Rabbit Awareness Week (RAW) is returning this summer, running from 24-28 June 2024. The theme for this year will be 'Healthy Diet, Happy Bunnies'.

The focus on rabbits' diet comes after the most recent PDSA Animal Wellbeing (PAW) Report report revealed that 42 per cent of veterinary professionals identified inappropriate diet as one of the five most important rabbit welfare issues that need to be address.

The campaign will include veterinary blogs, videos, and digital waiting room resources. Practices can sign up to receive updates about RAW. 

Click here for more...
News Shorts
CVS Group hit by cyber attack

CVS Group, which owns more than 450 veterinary practices in the UK, has been hit by a cyber attack.

In a statement, the group said the incident involved unauthorised external access to a limited number of its IT systems. As soon as the attack was discovered, the group took its IT systems temporarily offline, causing 'considerable operational disruption'.

It has warned that the security steps taken and ongoing plans to move its operational systems and IT infrastructure to the Cloud are likely to have an ongoing impact over a number of weeks.

Due to the risk that personal information was accessed, CVS has informed the Information Commissioner's Office. The company is working with third party consultants to investigate the incident.